Peer Reviewed Alzheimer's Convergence Science Research Award

archived

The PRARP Convergence Science Research Award mechanism was first offered in FY12. Since then, 72 Convergence Science Research Award applications have been received, and 12 have been recommended for funding. The intent of the FY14 CSRA is to support efforts to generate research resources and tools, or novel research efforts for professionals and practitioners in health sciences related to the PRARP’s mission. The research impact is intended to benefit the military community, while meeting a public purpose for the benefit of the civilian community. Overarching Challenges: This CSRA funding opportunity requires applications to address one or more of the following PRARP Overarching Challenges: Paucity of Research Resources: The paucity of research resources to examine the interrelationship between TBI and subsequent AD for military Veterans/other individuals affected by TBI. Paucity of Clinical Studies: The paucity of clinical studies to examine the interrelationship between TBI and subsequent AD for military Veterans/other individuals affected by TBI. Diagnostic Technologies, Tests, Interventions, or Devices: The need for technologies, tests, interventions, or devices with the potential to diagnose AD at its earliest stages. Focus Areas: In addition to addressing one or more of the specified Overarching Challenges, applications must also address at least one of the following FY14 PRARP Focus Areas in support of the Overarching Challenges. An application that proposes research outside of these Focus Areas is acceptable, as long as the applicant provides a strong rationale: Genomics/Proteomics/Bioinformatics: Studies or technologies (e.g., genetic, proteomic, and epigenetic strategies) intended to characterize neurological change(s) associated with TBI and subsequent AD. In addition, relevant technologies or tests may be considered under this Focus Area. Pathology of Tau: Novel research and technologies dedicated to unraveling the basic pathological mechanisms of Tau associated with TBI and AD. New! Roles of non-neuronal cells in TBI/AD pathogenesis: Technologies, tests, studies, or devices that will examine the roles of astrocytes (or other non-neuronal cells) in AD neurodegeneration due to TBI. While the CSRA mechanism can be used to support clinical research, the following is specifically discouraged under the FY14 PRARP: Pharmacologic Interventions: Clinical or Basic research requiring investigational or FDA-approved drugs or medicines. Drug Discovery and Development: Clinical or Basic research directly leading to the development of investigational medicines, drugs, or agents.

High